Acute Coronary Syndrome
Conditions
Brief summary
The purpose of this study is to see if rosuvastatin compared to Atorvastatin is effective in treating ACS by decreasing the ApoB/ApoA-1 ratio and if starting statin within 24 h following the onset of the first symptoms is beneficial compared to placebo.
Interventions
DRUGRosuvastatin
DRUGAtorvastatin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Hospital admission for ACS with chest pain or discomfort occurring during rest or with minimal exertion, * Percutaneous coronary intervention (PCI) planned, * Evidence of coronary artery disease
Exclusion criteria
* Hypersensitivity to statins * Any cholesterol lowering medication taken within 1 month prior V1 * Sustained ST-segment elevation on ECG
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage changes in ApoB/ApoA-I levels | from Day 0 to 3 months |
Secondary
| Measure | Time frame |
|---|---|
| Percentage changes in LDL-C | from Day 0 to 1 month and 3 months |
| Percentage changes in the hs-CRP and AUC of hs-CRP levels | from Day -6 to Day 0 |
| Percentage changes in ApoA-I | from Day 0 to 1 month |
Countries
Belgium, Canada, Estonia, France, Greece, Hungary, Ireland, Italy, Portugal, Spain, Tunisia
Outcome results
None listed